The Regeneten bioinductive implant demonstrated its ability to alter the tear progression course, facilitating a return to normal activity. Credit: Smith+Nephew.

Smith+Nephew has reported positive data from a new randomised controlled trial (RCT) that supports the use of its Regeneten bioinductive implant in rotator cuff repair.

The Regeneten bioinductive implant offers a patient-centric therapy that supports the natural healing response of the body for rotator cuff tears.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

In early studies, the implant demonstrated its ability to alter the tear progression course, facilitating return to normal activity and reducing re-tears in comparison to standard surgery.

It is said to be part of the company’s Advanced Healing Solutions portfolio.

The interim analysis from the RCT revealed a substantial decrease in the re-tear rate of full-thickness rotator cuff repairs when using the Regeneten implant.

In the multicentre, triple-blinded RCT, the re-tear rates of patients with medium to large full-thickness tears were measured after either an arthroscopic supraspinatus transosseous equivalent (TOE) repair performed alone or with a Regeneten Bioinductive Implant.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

At a 12-month follow-up, the repairs with the additional REGENETEN Bioinductive Implant had less re-tear rates compared to those with a TOE repair alone.

The findings showed that patients who received a REGENETEN Bioinductive Implant had a 3.5% re-tear rate.

Patients who got only TOE repair showed a 25% re-tear rate, which is consistent with the re-tear rates reported for similar tear types in other published studies.

The company stated that there were no differences in postoperative complications observed between the groups during the trial.

Smith+Nephew Sports Medicine Joint Repair vice-president Christie Van Geffen said: “New RCT evidence supporting the use of our REGENETEN Bioinductive Implant for improved patient outcomes continues to grow.

“No other bioinductive treatment has the amount of science behind it supporting the clinical value for thousands of patients with rotator cuff tears.”